GHRP-2 vs GHRP-6: GH, Appetite & Human Evidence

At a Glance: Side-by-Side Comparison

Mechanisms and the Limits of Head-to-Head Evidence

A direct comparison exists in cultured human fetal pituitary tissue: GHRP-2 and GHRP-6 produced similar GH stimulation at the concentration tested. This is a useful mechanistic observation, but tissue culture is not an adult head-to-head treatment trial and cannot rank muscle growth, appetite or tolerability. 1998 human pituitary-culture study

GHRH signaling and secretagogue signaling interact. In nine healthy men, a GHRH antagonist substantially reduced the GH response to an intravenous GHRP-6 bolus. That human experiment supports a connected hypothalamic-pituitary system, not the idea that each peptide controls an isolated GH or hunger pathway. 1998 GHRH-blockade study

GH Release and Appetite: What Human Studies Show

GHRP-2 is not an appetite-neutral option. In a randomized, double-blind study of 19 healthy adults, subcutaneous infusions increased food intake by about 10% at the lower exposure and 34% at the higher exposure compared with placebo. The visits lasted 270 minutes, and GH also increased. This is direct human evidence for an acute appetite effect, not a long-term bulking protocol. 2006 GHRP-2 food-intake study

Longer observations also need context. Ten children with GH deficiency received oral GHRP-2 for 12 months; seven reported greater appetite during the first six months, but the change in BMI standard-deviation score was not statistically significant. Increased hunger and sustained weight gain are different outcomes, and pediatric oral results should not be transferred to adult injections. 2003 pediatric appetite study

Users describe hunger after GHRP-6, sometimes as a useful effect and sometimes as unwanted. Those experiences can be retained as anecdotes without assigning everyone the same onset or duration. The GHRP-2 studies above do not compare the two peptides, so they cannot establish that GHRP-6 produces more hunger.

Cortisol, Prolactin and Side-Effect Management

GHRP-2 is not selective for GH alone in every experiment. In seven young adult volunteers, intravenous GHRP-2, hexarelin and Tyr-Ala-hexarelin each stimulated prolactin, ACTH and cortisol as well as GH. GHRP-6 was not an administered comparator, so this study cannot establish the difference between the two peptides in this article. 1999 endocrine-response study

An overnight GHRP-6 experiment in normal men found increased ACTH and cortisol alongside GH after repeated intravenous boluses. Stage 2 sleep increased, while slow-wave sleep did not change. These results show a broader endocrine effect, not a predictable cortisol percentage or a guarantee of better sleep in everyday use. 1995 GHRP-6 sleep-endocrine study

P5P means pyridoxal-5-phosphate, not pyridoxamine. Correcting the name does not establish that adding a vitamin B6 supplement prevents peptide-related prolactin changes. High supplemental B6 intake also has its own risks; it should not be presented as a routine protective component of a stack. NIH vitamin B6 reference

Cabergoline has a legitimate role in treating diagnosed hyperprolactinemic disorders, but it is not a casual add-on for presumed peptide side effects. Its prescribing information calls for cardiovascular assessment, including an echocardiogram, before treatment and warns about valvular and fibrotic complications. An abnormal prolactin result needs interpretation before another drug is added. Cabergoline prescribing information

Tolerance: Different Schedules, Different Findings

In nine healthy men receiving daily subcutaneous GHRP-2 for five days, the GH response became smaller while remaining present, and mean IGF-I did not increase. That documents early response attenuation under one schedule, not an inevitable point at which every regimen stops working. 1998 five-day GHRP-2 study

A different study gave continuous subcutaneous GHRP-2 to 17 older adults for 30 days. GH stimulation persisted at days 14 and 30 and IGF-I reached a sustained plateau; safety screening remained normal. These encouraging findings concern a small, short-term infusion study, not proof of long-term safety or a benefit from cycling. 2004 GHRP-2 infusion study

Tolerance is not a universal countdown. In nine healthy young men, a 34-hour intravenous GHRP-6 infusion increased integrated GH, pulse amplitude and IGF-I while reducing the GH response to an additional GHRP-6 bolus. Ongoing stimulation and a smaller response to a fresh challenge occurred together. These short-term results do not validate an eight-week cycle or prove that a four-week break restores responsiveness. 1993 GHRP-6 infusion study

Dosing, Pharmacokinetics, Preparation and Storage

A research exposure is not automatically a treatment schedule. Oral administration, subcutaneous infusion and an intravenous bolus cannot be treated as interchangeable. The studies reviewed here do not establish a bodybuilding schedule, pre-workout timing or mixing instructions for a GHRP/GHRH stack.

A universal three-to-seven-day refrigerated storage rule is not established by the sources reviewed here. Expiry and storage depend on the actual preparation and its supporting evidence; refrigeration alone does not establish either. For a dispensed medication, resolve unclear handling or discard instructions with the dispensing pharmacist instead of borrowing a generic peptide timetable. FDA expiry and stability explanation

For GHRP-2, a single intravenous study in ten prepubertal children with short stature estimated a mean terminal half-life of 0.55 hours, about 33 minutes. That is pediatric IV pharmacokinetics, not a universal adult or subcutaneous value. A hormone-response duration should not be substituted for the measured persistence of the peptide itself. 1998 GHRP-2 pediatric pharmacokinetic study

Half-life also needs a route and a measurement method. A study of nine healthy men receiving single intravenous GHRP-6 doses estimated mean distribution and elimination half-lives of 7.6 minutes and 2.5 hours. The same study observed unusual concentration spikes in four participants. Neither figure is a universal subcutaneous half-life or a validated injection frequency. 2013 GHRP-6 pharmacokinetic study

Choosing by the Outcome, Not the GH Peak

Choose the clinical question before comparing the peptides. A test of GH secretion, a short-term appetite experiment and a claim about gaining muscle answer different questions. Neither a stronger GH peak nor an account of increased hunger establishes the better treatment for body composition or recovery.

If unwanted hunger is the concern, GHRP-2 should not be described as an appetite-free alternative: controlled human food-intake experiments demonstrate an effect. If increasing food intake is the goal, an acute appetite response still does not establish durable nutritional benefit in a particular patient. 2006 GHRP-2 food-intake study

Reports from users about sleep, recovery or appetite can help identify questions worth studying. They cannot isolate the peptide from training, nutrition, other drugs or changes over time. Keep those experiences visible as reports, without turning them into predictable outcomes or a prescription.

GHRP-2 vs GHRP-6: The Evidence Summary

Both peptides have demonstrated biological activity in humans. The useful comparison is study-specific: which compound, which route, which population and which measured outcome? GHRP-2 has direct human appetite data, and GHRP-6 has endocrine and pharmacokinetic findings that do not fit a simple universal protocol. The evidence is more informative than a fixed ranking for bulking or cutting.

Combination Research and US Regulatory Context

Combination research should be described precisely. In a 24-hour subcutaneous infusion cohort of 11 older adults, one GHRP-2/GHRH pairing stimulated GH more than either component alone. That supports a human endocrine interaction, not every marketed GHRH analog, mixing method or long-term muscle-building stack. 2004 GHRP-2 infusion study

US regulatory status is separate from whether a molecule has interesting biological effects. FDA currently lists GHRP-2 for injectable and nasal routes, and GHRP-6, in category 2 under its 503B interim policy. Its safety concerns include product-quality and metabolic issues; reports associated with GHRP-2 do not establish causality or a predictable risk rate for every user. FDA compounding safety information

A research-use-only label does not automatically put a product outside drug regulation. FDA has assessed intended human use despite such disclaimers in enforcement actions involving other peptides. That principle is not a blanket statement about possession, and it does not establish that a research supplier is providing a suitable treatment product. 2026 FDA intended-use warning letter